Objectives To determine the risk of a histological diagnosis of cervical cancer following a given Pap test result and for a given history of Pap test results in a screened population across the full spectrum of possible cytological results. Methods All the Pap screening results held on the New South Wales Pap Test Register for 1997-2003 (five million tests for 1.87 million women) were analysed using Cox proportional hazards regression to estimate the odds of having a histologically determined cervical cancer for a given Pap test result and test result history. The hazard ratios of having cervical cancer in relation to Pap test result histories were estimated: (i) in regard only to the last Pap test result adjusting for age, frequency of Pap testing and proportion of high grade (Xcervical intraepithelial neoplasia 2 [CIN2]) abnormalities found in a woman's total recorded test result history; and (ii) with regard to the last Pap test result against the highest grade of cytological abnormality found prior to the last Pap test result. The hazard ratios are for a cancer diagnosis occurring before the next Pap test and were adjusted for age, quintile of socioeconomic status of residence, frequency of past Pap testing and proportion of high-grade abnormalities detected in each woman's prior Pap test history. The adjusted hazard ratios were then applied to the tabulated proportions of referent women with negative cytology in each broad age group, and for all women, to estimate the '1 in n' odds of being diagnosed histologically with cervical cancer for a given last Pap test result, and by a given last Pap test result for various prior Pap test result histories. Results After adjusting for age, socioeconomic status, frequency of previous Pap testing and proportion of past high-grade screen-detected abnormalities, the adjusted hazard ratio of having a subsequent cervical cancer diagnosis for women with a negative Pap test result was 1 in 5546, compared with 1 in 833 for a low-grade epithelial abnormality (atypia, CIN1), 1 in 56 for a highgrade epithelial abnormality and 1 in seven for a cytological prediction of cervical cancer. These odds estimates were significantly modified by age and by the highest Pap test result prior to the most recent Pap test result: the higher the age and, less consistently, the higher the previous highest Pap test result for a given last Pap test result, the shorter the odds of having a subsequent histological diagnosis of cervical cancer. Conclusions The results presented here will enable clinicians to inform their patients of their chances of being diagnosed with cervical cancer for a given Pap test result, and for some combinations of the last Pap test result and highest recorded prior Pap test result.
INTRODUCTION
E stablished risk factors for cervical cancer include older age, earlier age of first intercourse, lifetime numbers of sexual partners and previous Papanicolaou (Pap) smear cervical screening practice, among numerous factors that increase the probability of infection from one or more of the oncogenic strains of the human papilloma virus (HPV). Previous Pap testing history and cervical cancer have been studied to some extent as risk factors, but the whole spectrum of prior Pap test results has not been examined in relation to cancer outcomes. Pap test histories can range from a complete lack of Pap screening, irregular screening, screening regularly at the recommended screening interval, screening more regularly than recommended, or having a Pap test only in the presence of symptoms. However, screening-related risk factors for cervical cancer are not confined to the frequency of screening but also depend on the Pap test result history, because the cervical screen detects potentially pre-cancerous lesions of the cervix uteri at various stages of development, which are (treatable) risk factors for cervical cancer. Actual precancerous lesions in regularly screened women can be detected earlier in their progression towards cancer than in under-or unscreened women.
Studies of cervical cancer and screening history to date have concentrated mainly on incidence or risk of cancer or screen-detected abnormality in terms of frequency of prior Pap testing, 1 or following a normal and/or unsatisfactory cytology result, 2, 3 or within the narrower aim of establishing the natural history of cervical abnormalities. 4 Not examined as often are possible associations between the risk of subsequent diagnosis of cervical cancer over the full spectrum of past screening result patterns, especially in conjunction with past screening frequency and other known risk factors for cervical cancer, including age or socioeconomic status (SES).
In New South Wales (NSW), the organized approach to cervical screening was implemented in 1996 with the establishment of the NSW Cervical Screening Programme (CSP) and the NSW Pap Test Register (PTR). The role of the CSP is to promote cervical screening in the eligible (at-risk) population of NSW women, while the NSW PTR is the repository of the universe of cervical screening test data for all NSW women who undergo a Pap test or cervical histological investigation. Data held on the NSW PTR also include the demographics of screened women. Accordingly, a practical outcome of using such data is to provide reliable information for clinicians, who are inevitably asked the question 'What are my chances of having cancer?' when a patient receives a Pap test report of an abnormality. The aim of this paper is to quantify the chances of having a subsequent histological diagnosis of cervical cancer in women with one or more Pap test recorded on the NSW PTR, by the last Pap result and by the last Pap result against the highest prior Pap result. These estimated chances of a cancer diagnosis accordingly need to be adjusted for varying periods from cytology result to diagnosis, or to a predetermined censored time where no diagnosis has occurred, but all estimates apply to the period before the next Pap smear or to the period before histological follow-up in the case of a diagnosed cancer.
METHODS

Study design
This study is a cohort design with retrospective and prospective components utilizing proportional hazards regression analysis to estimate the odds of a histological diagnosis of cervical cancer, including micro-invasive and invasive squamous and non-squamous cancer of the cervix uteri, for a given Pap test result and Pap test result history. The study population comprises almost all NSW women who have appeared on the NSW PTR from the first quarter of 1997 to the last quarter of 2003 inclusive. Excepting women choosing not to have their details kept on the register ($1.5%), the study sample represents all NSW women who had a Pap test during 1997-2003. Approximately 90% of the target population of NSW women aged 20-69 years appears on the NSW PTR.
As the relationship between cervical cancer and Pap test screening has been shown to be confounded by age, and most probably by SES, 5 women in the study were classified into three broad age groups (15-29, 30-49 and X50 years), and into approximate equal-population quintiles of SES according to their area of residence in NSW. The main study factor is Pap test result history. For the cases of histologically determined cervical cancer, all Pap tests preceding the first histological diagnosis of cancer were included as study factors (including their frequency) in the analysis, and all subsequent Pap test and histology results censored. Survival times are in days from the last Pap test to the event (cancer diagnosis) or to the censoring cut-off time (31 December 2003).
Data
De-identified unit record cervical screening and histological data for NSW women for the seven years covering 1997-2003 were supplied to the NSW CSP by the PTR and used for the analysis. The screening data comprise approximately five million individual test records, and include age and area of residence, date of request for the test and the cytological test result according to squamous, endocervical and 'other' cell malignancy status, and whether HPV was detected. Histological data were included in the analyses and comprised the date of request for histology, the woman's age at diagnosis and up to 10 histological result codes conforming to the Systematized NOmenclature for MEDicine (SNOMED) International III coding system. All histology records were linked to the cytology data by a unique encrypted identifier, and were classified as cervical cancer (case) or not cervical cancer (non-case). All women with cytology records with no recorded histology were also classified as non-cases. Altogether 1059 women with a Pap test history had a histological diagnosis of cervical cancer during 1998-2003, as did 493 women with no PTR-recorded Pap test history.
The measure of SES used was of local government area of residence, referred to as the Index of Socioeconomic Disadvantage, a composite aggregate variable developed by the Australian Bureau of Statistics (ABS) based on home ownership rates, population proportions of tertiary educational attainment and occupational prestige, levels of unemployment, among others, for a given local government area. 6 These SES indicators are derived at each population census; those from the 1996 Australian Census were used in this paper.
A large variety of Pap test result sequences is possible, especially when the order of test results is also considered. The first pre-requisite for examining a relationship between a cervical cancer outcome, Pap test result and Pap test result history is to limit the number of possible test sequence combinations so that screened women can be categorized into groups based on biologically plausible test-sequence precursors. Result sequence categories should capture a large proportion of screened women, and more importantly should be related ordinally from lower to higher grade lesion, as in a dose-response relationship.
Accordingly, Pap test result sequences in women on the PTR were classified for the present analysis as follows: Based on these test history criteria, the final data-set for analysis comprised one record only for each woman, with test history information assembled or cumulated from earlier records and added to the last Pap test record for each woman (non-cases), or to the last Pap test record prior to the histological cancer diagnosis (cases). In this way, each woman has one type of test result history only (i.e., the highest past PTR-recorded abnormality) in relation to her most recent recorded (last) Pap test. Consequently, the analyses presented here is woman-based, not test-based, and test histories are time-invariant covariates in proportional hazards regression models.
Analysis
Unadjusted and adjusted hazard ratios (HRs) for a histological cervical cancer diagnosis were estimated for each last cytology test result in relation to referent women whose last Pap test result was negative/benign, using Cox proportional hazards regression. Baseline cervical cancer risks in each comparison group were calculated to aid estimation of '1 in n' odds of subsequent cancer diagnosis by the highest prior result category using the HR adjusted for age, quintile of SES, the total number of prior Pap tests recorded on the PTR (i.e. prior Pap test frequency) and the percent proportion of prior high-grade results within each woman's total PTRrecorded test history. This latter is to establish the extent to which women with a higher proportion of prior high-grade Pap test results also have higher risk of cervical cancer compared with women with lower proportions of highgrade results in their Pap test history (i.e. a dose-response relationship). This also partly controls for the increased risk of finding an abnormality with Pap test frequency. That is, there is a higher chance of finding an abnormality with more tests.
Unadjusted and adjusted HRs of cases of cervical cancer in each screening history category were examined using w 2 statistics to test for the statistical significance of the modelled test result predictors of cervical cancer, while adjusting for the main confounders of woman's age and SES. Proportional hazards regression is appropriate with varying periods (failure times) to events (e.g. cancer diagnosis) and because of data censorship in which the cancer or test result status of women who appear on the PTR at a given time are not known subsequently. Also, given the relatively short existence of the NSW PTR, significant left censorship is also present, especially in older women whose test history prior to 1997 is also unknown.
In women with prior cytological tests to their last Pap test, adjusted HRs of being diagnosed histologically with cervical cancer, for a given last Pap test result by highest prior recorded Pap test result, were derived from the modelled HRs of histologically determined cervical cancer stratified by the last cytological result. That is, the last Pap test result was specified as strata in the proportional hazards regression model with each combination of last versus highest prior test result (7 Â 8) specified as covariates. The referent group of women used in these analyses was those whose last Pap test and highest prior Pap test results were both negative. The estimated HR for each result category combination was adjusted for age and SES at the last Pap test, frequency of prior Pap tests, and proportion of prior Pap tests with a highgrade result. In order to provide reliable estimates for clinicians of the odds of a histological cancer diagnosis for combinations of the last test result and the highest prior test result, the regression models were built through a stepwise approach. Only those HR estimates which remained in the model at the a ¼ 0.05 significance level were used to produce estimates of odds of a cancer diagnosis, and these estimates were derived after specifying the last Pap test result in the strata statement in the PHREG procedure (for Cox proportional hazards regression) in SAS version 8.2. 7 Adjusted risk estimates in each last-versus-highest priorrecorded Pap test result combination were also separately derived for each of the three broad age groups, 15-29, 30-49 and X50 years. All proportional hazards regression models where the last Pap test result was not specified as a covariate nonetheless were stratified by last Pap test result, since the proportionality assumption most probably would be violated according to different follow-up protocols and chances of a cancer diagnosis for different Pap test results.
Accompanying adjusted HRs are presented as '1 in n' chance estimates as an aid to clinicians, and the adjusted HRs interpreted as the relative hazard of a cervical cancer diagnosis occurring before the next Pap test.
RESULTS
From the proportional hazards regression model of the last Pap test results only, the HR of having a subsequent cervical cancer diagnosis for a woman whose last cytology result predicted cervical cancer, compared with women whose last cytology result was negative, was 813 after adjusting for age, SES, frequency of prior Pap tests and the percent proportion of prior Pap tests with a high-grade (XCIN2) result ( Table 1) . The corresponding HR of a cervical cancer diagnosis from a cytology prediction of HGEA (definite CIN2/3) was 99, or 64 for having a Pap test result suggesting possible high-grade lesion. Women whose Pap test predicted a non-cervixrelated malignancy were 95 times more likely to have a subsequent cervical cancer diagnosis than women with negative cytology. In women with a low-grade cytology result, the HR of a cervical cancer diagnosis was 6.7 compared with women with a negative/benign result, lower than that for women whose last Pap test was unsatisfactory (10). Women with no prior cytology were 107 times more likely to be diagnosed with cervical cancer than women with a negative smear, reflecting the high proportion of cervical cancers ($32%) diagnosed in unscreened women presenting with symptoms. The frequency of prior Pap testing was significantly negatively associated with a subsequent histological diagnosis of cervical cancer, with HR ¼ 0.61 per previous Pap test.
Lower SES than the highest SES quintile at the time of the last Pap test was positively associated with a cervical cancer diagnosis, with HRs ranging from 1.5 to 1.8 after adjusting for confounders. However, as can be seen from Table 1 , there was no evident linear HR trend within the lower SES quintiles. Older age at the time of the last Pap test was significantly associated with higher HR of subsequent cervical cancer determination, with an HR of 5.2 in women aged 30-49 years, and 18 in women aged X50 years, compared with women in the youngest 15-29 year age group (HR ¼ 1.0).
Overall, a woman whose last Pap test result was negative was estimated to have adjusted odds of 1 in 5546 of having a subsequent cervical cancer diagnosis before her next Pap test, compared with 1 in 833 for a woman with a low-grade abnormality, one in 56 for a high-grade abnormality, and 1 in seven for women with a cytological prediction of cervical cancer ( Table 2) . Women aged 15-29 years were estimated as having an adjusted odds of 1 in 11 of subsequent cervical cancer diagnosis if their last Pap test predicted cervical cancer, compared with 1 in 5 for women aged 30-49 years, and 1 in 4 for women aged 50 þ years. A high-grade lesion was associated with odds of 1 in 308 of subsequent cervical cancer in those aged 15-29 years, 1 in 77 for women aged 30-49 years, and 1 in 23 for women aged 50 þ years. A lowgrade lesion (LGEA ¼ atypia or CIN1) was associated with odds of about 1 in 2723 of subsequent cervical cancer in the youngest age group, 1 in 1401 for women aged 30-49, and 1 in 361 for women aged 50 þ years. Having an unsatisfactory smear was associated with higher odds of subsequent cervical cancer than having a low-grade lesion in the two older age groups (1 in 744 and 1 in 224 for women aged 30-49 and 50 þ years, respectively). Having a negative Pap result was associated with an odds of about 1 in 74-75,000 of subsequent cervical cancer in women aged 15-29 years, compared with 1 in 10-11,000 for women aged 30-49 years, and about 1 in 1900 for women aged 50 þ years.
The last Pap test result versus highest prior Pap test result indicates the extent to which result history modifies the hazards of a subsequent cervical cancer determination for a given last Pap test result (Table 3 ). Only odds based on statistically significant proportional hazards regression estimates are presented. A woman whose last Pap test result was negative, but whose highest prior Pap test result was a possible high-grade abnormality, had an odds of about 1 in 1500 of subsequent cervical cancer, compared with 1 in 8070 for a woman whose last Pap test result and whose prior Pap test history was exclusively negative. A woman with a low-grade lesion but with no prior recorded cytology history was estimated to have an odds of 1 in 2247 of subsequent cervical cancer, compared with a similar woman with an exclusively negative prior cytology history (1 in 1900).
Analyses stratified by age group produced the expected lengthening of odds of cervical cancer for the younger 15-29-year age group and shortening of odds for the older X50-year age group. Of note are the extremely long odds of a cervical cancer diagnosis if the last Pap test predicts cancer and the highest prior Pap test result also predicted cervical cancer (1 in 46,000 overall), reflecting the effectiveness of treatment/follow-up from previous cytological predictions of cervical cancer (but not confirmed histologically).
DISCUSSION
The main practical purpose of this paper is to provide clinicians with something of a 'ready reckoner' of the odds of a subsequent cervical cancer diagnosis for a given Pap test result, so that at-risk women, especially those with screendetected abnormalities, can be given accurate information on their chances of having cervical cancer diagnosed subsequent to their Pap test. The last Pap test result was chosen as the reference point, because it is the implications of this result which are being discussed by the clinician and patient. The anxious patient, after all, is interested in prognostic information about their current test status. The data used for these estimates were the five million cervical screening records held on the NSW PTR over seven years (1997) (1998) (1999) (2000) (2001) (2002) (2003) . To our knowledge, this is the first study to exploit the Pap test histories of a whole population covered by an organized CSP to estimate the chances of having cervical cancer subsequently diagnosed by histology for a given Pap test result and test result history.
The main results of this study showed higher HRs of subsequent cervical cancer diagnosis to occur with increasing grade of potential pre-cancer lesion, in accordance with the known biology of progression to and regression from cervical cancer of the different varieties of the HPV. Moreover, these HRs of cancer were modified by age and by prior Pap test histories mostly in the expected directions. That is, a woman with a given Pap test result and a prior history of screen-detected lesions generally will have a higher hazard of subsequent cervical cancer diagnosis than a woman with a similar result, but a prior history of benign cytology, as would an older woman. It should be borne in mind, however, that the present analysis makes no attempt to establish rates of progression to and regression from cancer from the various grades of potential pre-cancer abnormality by different age group. Instead, the results presented here depend partly on the population under study, with its characteristic prevalence of infection by the different oncogenic HPV strains, each with its own rate of progression to and regression from cancer. Accordingly, the odds of having a subsequent cervical cancer diagnosis for a given last test result and test result history are the summary net results of progression in some and regression in other cases of abnormality. The present findings may be most applicable to populations with similar prevalences of HPV varieties as those in the NSW population of women at risk of cervical cancer, but may also approximate the odds of cervical cancer in other screened populations.
Estimates of risk or chance of subsequent cervical cancer diagnosis in relation to cytology results are subject to a number of sources of bias. The first stems from differing treatment and monitoring options available in women with low-grade cytological abnormalities (pCIN1). Current screening guidelines for Australian women with a lowgrade cytology result (pCIN1) recommend the option of more frequent observation (e.g. annual Pap tests) or an active intervention (e.g. colposcopy). Unfortunately, data available to the NSW PTR do not include non-cytological or non-histological follow-up of screen-detected abnormalities; for instance procedures such as colposcopy or surgical excision unrelated to a histological determination. Accordingly, it was not possible to examine cervical cancer outcomes for women choosing observational follow-up versus more active treatment for a low-grade lesion. This would imply that estimates of risk of subsequent cancer diagnosis for women with the highest prior result of lowgrade cytology are biased towards the null, since an unknown proportion of these women will have active follow-up (and possible treatment) and conceivably lower risk of a subsequent cervical cancer outcome than women choosing observational follow-up. For example, in NSW a small number of cases of cervical cancer have occurred in women whose last Pap test result was low grade, but it is not possible to know accurately the extent of subsequent cancer differences between active versus passive follow-up in this group.
It is also apparent from the analysis that the follow-up and treatment regime accompanying a Pap test prediction of cervical cancer is effective in NSW women. This is reflected in the extremely long odds estimated for being diagnosed with cervical cancer in those women, whose last Pap test result predicted cervical cancer and whose previous highest cytological result was also a cervical cancer prediction. The second source of bias stems from different Pap test results having different relationships to the histological gold standard. The vast bulk of negative cytology results are not examined histologically, and this is also the case for a substantial proportion of low-grade lesion results (especially non-specific minor changes or atypia), while most screendetected high-grade abnormalities and cancer predictions are followed up in short order by the histological gold standard (verification bias). Consequently, the sensitivity and specificity of the Pap test is difficult to determine accurately in the general population. The unknown proportion of cancer cases among women with negative or lowgrade Pap test results who did not undergo histological confirmation of their negative or low-grade cytology result will tend to produce HR estimates biased towards the null, so that the HRs reported here may be an underestimate of the true hazard for this group. On the other hand, this source of bias is minimized somewhat due to the use of proportional hazards regression to account for different failure times (i.e. time from last Pap test to subsequent cancer determination) and data censorship.
The analysis presented here showed SES of area (at the last Pap test) to be significantly associated with risk of cervical cancer after controlling for age, frequency of Pap testing and Pap test result history. The SES differential was such that the highest SES quintile had significantly lower hazard of a cervical cancer diagnosis than the remaining four SES quintiles, which had HRs of a cervical cancer diagnosis not significantly different from each another. While SES was not the primary focus of this paper, such a result may occur when integrating Pap test screening rates with result histories and event failure times to arrive at a model of predictors of a cervical cancer diagnosis in the indefinite future. However, further investigation with focus on SES would be needed to better understand the possible mechanisms underpinning such a result.
The present study did not confine future diagnoses of cancer to within six months or two years of a cytological result, as appropriate to ascertaining histological confirmation rates for cytology (from histology within, say, six months of cytology) or interval cancer rates (histological cancer diagnosis within two years of a negative or noncancer cytological prediction). Instead, what has been attempted is to provide clinicians and women with estimates of the odds of having cervical cancer in the indefinite future for a given last cytology result, probable follow-up for that result based on that observed in the population, and prior test result history. Viewed another way, the estimates of HRs and odds of having a cervical cancer diagnosed histologically are also the HRs and odds of having a cervical cancer diagnosis before the next Pap smear, since all the modelling is in relation to the last Pap test result as the 'zero point'. The vast majority of subsequent cancer diagnoses used in the present analysis occurred within two years of the last cytological test result. No definite follow-up periods were specified in the analysis presented here and December 2003 was the final cut-off time for censored (non-cancer) observations.
In general, the main reason for not confining the analysis to a cancer diagnosis within fixed periods was to account for: (i) the fact that not all women comply with the recommended screening intervals (it seems, for instance, that many women without abnormalities in NSW tend to comply with the International Agency for Research on Cancer (IARC)-recommended interval of three years rather than two years recommended in Australia); (ii) not all screening programmes have the same recommended screening interval or target group, or the same recommended follow-up protocols and test intervals for women with various cytological abnormalities (and histories); (iii) within the Australian cervical screening environment, the follow-up protocol for a low-grade abnormality is optional; (iv) most histological cancer diagnoses occur within much shorter periods than two years (most often within days) after a cytological prediction of cancer; and (v) it is of little relevance to an anxious patient discussing her abnormality with her doctor that her chances of a cancer diagnosis in the next set period of two or three years are 'x' when the followup investigation for the abnormality often is within days or weeks of the cytological abnormality.
Clearly, seven years of test data potentially will produce estimated odds of future cervical cancer diagnosis different from those based on test data covering a longer period, or on test data in a screened population where the recommended screening interval is not two years, or the follow-up protocols and reminder systems different. Within the context of an organized screening programme with recruitment, screening and follow-up guidelines directed toward the whole at-risk population, and where approximately 90% of the target population has had a Pap screen within the past five years, it is not expected that the HR estimates derived here would be significantly different from those produced from similar analyses of longer aggregations of whole-population screening test data.
